Suppr超能文献

轻度至中度慢性阻塞性肺疾病中的C反应蛋白与死亡率

C-reactive protein and mortality in mild to moderate chronic obstructive pulmonary disease.

作者信息

Man S F P, Connett J E, Anthonisen N R, Wise R A, Tashkin D P, Sin D D

机构信息

James Hogg iCAPTURE Center for Cardiovascular and Pulmonary Research, St Paul's Hospital, 1081 Burrard Street, Vancouver, BC, Canada V6Z 1Y6.

出版信息

Thorax. 2006 Oct;61(10):849-53. doi: 10.1136/thx.2006.059808. Epub 2006 May 31.

Abstract

BACKGROUND

Although C-reactive protein (CRP) levels are increased in chronic obstructive pulmonary disease (COPD), it is not certain whether they are associated with adverse clinical outcomes.

METHODS

Serum CRP levels were measured in 4803 participants in the Lung Health Study with mild to moderate COPD. The risk of all-cause and disease specific causes of mortality was determined as well as cardiovascular event rates, adjusting for important covariates such as age, sex, cigarette smoking, and lung function. Cardiovascular events were defined as death from coronary heart disease or stroke, or non-fatal myocardial infarction or stroke requiring admission to hospital.

RESULTS

CRP levels were associated with all-cause, cardiovascular, and cancer specific causes of mortality. Individuals in the highest quintile of CRP had a relative risk (RR) for all-cause mortality of 1.79 (95% confidence interval (CI) 1.25 to 2.56) compared with those in the lowest quintile of CRP. For cardiovascular events and cancer deaths the corresponding RRs were 1.51 (95% CI 1.20 to 1.90) and 1.85 (95% CI 1.10 to 3.13), respectively. CRP levels were also associated with an accelerated decline in forced expiratory volume in 1 second (p < 0.001). The discriminative property of CRP was greatest during the first year of measurement and decayed over time. Comparing the highest and lowest CRP quintiles, the RR was 4.03 (95% CI 1.23 to 13.21) for 1 year mortality, 3.30 (95% CI 1.38 to 7.86) for 2 year mortality, and 1.82 (95% CI 1.22 to 2.68) for > or =5 year mortality.

CONCLUSIONS

CRP measurements provide incremental prognostic information beyond that achieved by traditional markers of prognosis in patients with mild to moderate COPD, and may enable more accurate detection of patients at a high risk of mortality.

摘要

背景

尽管慢性阻塞性肺疾病(COPD)患者的C反应蛋白(CRP)水平会升高,但尚不确定其是否与不良临床结局相关。

方法

对4803名患有轻至中度COPD的肺部健康研究参与者测量血清CRP水平。确定全因死亡率和特定疾病死亡率的风险以及心血管事件发生率,并对年龄、性别、吸烟和肺功能等重要协变量进行校正。心血管事件定义为因冠心病或中风死亡,或因非致命性心肌梗死或中风需住院治疗。

结果

CRP水平与全因、心血管和癌症特异性死亡率相关。CRP最高五分位数的个体与最低五分位数的个体相比,全因死亡率的相对风险(RR)为1.79(95%置信区间[CI]1.25至2.56)。心血管事件和癌症死亡的相应RR分别为1.51(95%CI 1.20至1.90)和1.85(95%CI 1.10至3.13)。CRP水平还与1秒用力呼气量加速下降相关(p<0.001)。CRP的判别特性在测量的第一年最大,并随时间衰减。比较CRP最高和最低五分位数,1年死亡率的RR为4.03(95%CI 1.23至13.21),2年死亡率的RR为3.30(95%CI 1.38至7.86),≥5年死亡率的RR为1.82(95%CI 1.22至2.68)。

结论

对于轻至中度COPD患者,CRP测量提供了超出传统预后标志物的额外预后信息,并且可能有助于更准确地检测出高死亡风险患者。

相似文献

1
C-reactive protein and mortality in mild to moderate chronic obstructive pulmonary disease.
Thorax. 2006 Oct;61(10):849-53. doi: 10.1136/thx.2006.059808. Epub 2006 May 31.
2
Inflammatory biomarkers and exacerbations in chronic obstructive pulmonary disease.
JAMA. 2013 Jun 12;309(22):2353-61. doi: 10.1001/jama.2013.5732.
4
C-reactive protein in patients with COPD, control smokers and non-smokers.
Thorax. 2006 Jan;61(1):23-8. doi: 10.1136/thx.2005.042200. Epub 2005 Sep 2.
7
Blood biomarkers as predictors of long-term mortality in COPD.
Clin Respir J. 2018 May;12(5):1891-1899. doi: 10.1111/crj.12752. Epub 2018 Jan 5.
8
Red blood cell distribution and survival in patients with chronic obstructive pulmonary disease.
COPD. 2013 Aug;10(4):416-24. doi: 10.3109/15412555.2012.758697. Epub 2013 Mar 28.
9
Systemic inflammation and mortality in chronic obstructive pulmonary disease.
Can J Physiol Pharmacol. 2007 Jan;85(1):141-7. doi: 10.1139/y06-093.

引用本文的文献

3
Prognostic models and factors identifying end-of-life in non-cancer chronic diseases: a systematic review.
BMJ Support Palliat Care. 2024 Dec 19;14(e3):e2316-e2329. doi: 10.1136/spcare-2023-004656.
7
Systemic and Airway Epigenetic Disruptions Are Associated with Health Status in COPD.
Biomedicines. 2023 Jan 5;11(1):134. doi: 10.3390/biomedicines11010134.

本文引用的文献

3
Airway and systemic inflammation and decline in lung function in patients with COPD.
Chest. 2005 Oct;128(4):1995-2004. doi: 10.1378/chest.128.4.1995.
5
The effects of a smoking cessation intervention on 14.5-year mortality: a randomized clinical trial.
Ann Intern Med. 2005 Feb 15;142(4):233-9. doi: 10.7326/0003-4819-142-4-200502150-00005.
7
C-reactive protein levels and outcomes after statin therapy.
N Engl J Med. 2005 Jan 6;352(1):20-8. doi: 10.1056/NEJMoa042378.
9
Inflammation and atherosclerosis: role of C-reactive protein in risk assessment.
Am J Med. 2004 Mar 22;116 Suppl 6A:9S-16S. doi: 10.1016/j.amjmed.2004.02.006.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验